Compounded Semaglutide Legal Status in 2026: What Changed, What Is Still Available
Compounded semaglutide became one of the most-prescribed cash-pay medications in the United States between 2022 and 2024, with hundreds of telehealth clinics offering monthly subscriptions for $199 to $499. The legal foundation for this entire industry was the FDA shortage list designation, which permits 503A compounding pharmacies to prepare medications that are in shortage. In February 2025, the FDA officially removed semaglutide from the shortage list, fundamentally changing the regulatory landscape. This guide explains what changed, what remains legal, and what your options are in 2026.
- › FDA removed semaglutide from the shortage list in February 2025. 503A compounding is now restricted.
- › Compounding is still legal for patient-specific clinical necessity (allergy, dose, route) - but not as blanket subscription service.
- › Brand-name Wegovy with insurance coverage is the primary remaining low-cost path ($25-$100/month with prior auth).
- › Some telehealth clinics continue compounding through compliant patient-specific pathways; verify the legal basis.
- › If shifting back to brand-name: budget $1,300/month retail or work with provider on insurance authorization.
What the FDA Did and When
The FDA placed semaglutide on the official drug shortage list in March 2022 in response to overwhelming demand for Wegovy and Ozempic that exceeded manufacturer Novo Nordisk's production capacity. This designation activated section 503A of the Federal Food, Drug, and Cosmetic Act, which allows licensed compounding pharmacies to prepare medications that are in shortage.
Between 2022 and 2024, an estimated 500,000 to 1 million Americans used compounded semaglutide as their primary weight-loss medication. Telehealth weight-loss clinics built entire business models around this access pathway: Henry Meds, Mochi Health, Sequence (now Ro Body), Calibrate, and dozens of smaller clinics.
In October 2024, the FDA officially removed tirzepatide from the shortage list. In February 2025, semaglutide followed. The 60-day implementation period for 503A pharmacies expired in April 2025, and for 503B outsourcing facilities in May 2025.
What This Means Legally
As of 2026, 503A compounding pharmacies cannot legally compound semaglutide unless one of three specific exceptions applies:
The first exception is clinical necessity for individual patients. If a prescribing physician documents that a specific patient cannot tolerate or use the FDA-approved Wegovy or Ozempic for clinical reasons (allergy to inactive ingredients, dose requirement different from what is commercially available, route of administration not commercially available), compounded versions may still be prepared. This is the primary legal pathway that remains for compliant compounding.
The second is microdosing. Doses substantially lower than commercially available products (for example, very low doses for elderly patients or those with severe GI sensitivity) may still be compounded.
The third is novel combinations. Semaglutide combined with another active ingredient (B12, lipotropic agents, anti-nausea medications) in a single preparation may be compounded if the combination is not commercially available.
Outside these exceptions, compounding semaglutide is not legal for 503A pharmacies in 2026. Pharmacies and clinics that continue to compound and ship semaglutide without falling under these exceptions are operating outside FDA-compliant pathways.
What Is Still Available
Several legitimate paths still exist for accessing semaglutide at less than retail brand-name pricing.
Brand-name Wegovy with insurance coverage. Many commercial insurance plans cover Wegovy for patients meeting BMI and comorbidity criteria, with prior authorization. Out-of-pocket can drop to $25 to $100 per month with insurance approval. Verify your plan formulary and submit prior authorization through your prescribing physician.
Manufacturer savings programs. Novo Nordisk runs a Wegovy savings card program that can reduce out-of-pocket costs for patients with commercial insurance who are denied coverage. Eligibility varies; check the manufacturer website.
Telehealth clinics that have shifted to compliant patient-specific compounding. Some clinics have pivoted to the clinical-necessity exception pathway with proper documentation. Verify the clinic documents your specific clinical reason for compounded preparation rather than blanket compounding for all patients.
Tirzepatide alternatives. Some patients have shifted to compounded tirzepatide, which is also off the shortage list but has slightly different exception interpretations. Both are constrained.
Compounded versions through non-compliant channels. Some clinics continue to operate outside the new compliance framework. The legal and quality risks are higher; consumers should evaluate carefully.
International sources. Wegovy and Ozempic are available in Canada, Mexico, and other countries at varying price points. Importation in personal-use quantities exists in a gray legal area.
What to Ask Your Current Clinic
If you are currently using compounded semaglutide through a telehealth clinic in 2026, several questions are worth asking.
First: what legal pathway is your clinic operating under? Reputable clinics will explain whether they are using the clinical-necessity exception, are exclusively prescribing brand-name medications, or have shifted to a different protocol entirely.
Second: which compounding pharmacy fills my prescription? Verify the pharmacy is licensed in your state and follows current FDA guidance. Check the National Association of Boards of Pharmacy database.
Third: what happens if my pharmacy stops compounding? Have a contingency plan in writing.
Fourth: what is the all-in monthly cost including provider, medication, and labs?
Fifth: what is the dose I am receiving, and how is it documented? Patient-specific clinical necessity documentation should be part of your medical record.
The Quality Question
Independent of legal status, there is a quality question that has always existed with compounded semaglutide. The active pharmaceutical ingredient (API) used in compounding has varied considerably across pharmacies. FDA-approved Novo Nordisk semaglutide is the only API source that has undergone full FDA review.
Some compounding pharmacies have used semaglutide "salt forms" (semaglutide acetate, semaglutide sodium) which are different chemical entities not FDA-approved. The FDA explicitly stated in October 2023 that these salt forms are not bioequivalent to approved semaglutide and should not be used in compounding.
Reputable compounding pharmacies disclose the API source and can provide certificate of analysis showing purity and identity testing. Lower-tier compounders may obscure this.
If you are receiving compounded semaglutide, asking for the certificate of analysis is a reasonable patient request. Reputable pharmacies will provide it.
What to Do If Your Current Source Becomes Unavailable
Several telehealth clinics have already stopped compounding semaglutide in 2025-2026. If your current source becomes unavailable, you have multiple options.
Switch to FDA-approved Wegovy. The pricing is much higher without insurance ($1,300+/month) but the quality, manufacturing oversight, and legal status are well-established. Many patients prefer this option once they realize the price difference is manageable with insurance coverage or manufacturer programs.
Apply for Wegovy insurance coverage. Many patients who assumed insurance would not cover them actually qualify with prior authorization. Working with your physician to submit a comprehensive request often succeeds.
Switch to tirzepatide. Zepbound (brand) or compounded tirzepatide. Tirzepatide produces slightly greater weight loss in head-to-head trials, though it faces similar compounding constraints to semaglutide as of 2026.
Consider phentermine. Older oral appetite suppressant. Much cheaper ($20-$40/month generic) but typically only used short-term. Less effective than GLP-1 medications but still produces 5-10 percent weight loss.
Stop GLP-1 entirely and focus on lifestyle. For some patients who have achieved their goal weight, structured maintenance with diet and exercise alone is appropriate, though studies show 60-70 percent of GLP-1 weight loss is regained without ongoing medication.
Frequently Asked Questions
Is compounded semaglutide legal in 2026? +
Compounded semaglutide is legal only under specific clinical-necessity exceptions in 2026. The blanket compounding that was permitted under the FDA shortage list (March 2022 - February 2025) is no longer available. Reputable telehealth clinics that continue to offer compounded semaglutide have shifted to documenting individual patient clinical necessity (allergy, dose, route).
Will my compounded semaglutide subscription continue? +
It depends on whether your prescribing clinic has shifted to compliant patient-specific documentation or has continued blanket compounding. Ask your clinic specifically: what legal pathway is my prescription operating under? Some clinics stopped offering compounded semaglutide; others continue under various interpretations of the exceptions.
Should I switch back to brand-name Wegovy? +
For most patients, working with your physician to get Wegovy approved by insurance is the best path. Many patients qualify with prior authorization. If insurance denial is the outcome, the cost difference ($1,300 brand vs $300 compounded) is substantial, and tirzepatide or phentermine alternatives may be worth considering.
Are research peptides a legal option? +
No. Research peptides sold "for research use only, not for human consumption" are not legal for human use, regardless of source. Quality, dosing accuracy, and contamination risks are substantial. The FDA does not consider this a compliant pathway.
Can I import semaglutide from Canada or Mexico? +
Personal importation of prescription medications in small quantities exists in a gray legal area. The FDA generally has not enforced against patients importing 90 days or less of personal-use medications. Quality, chain of custody, and importation logistics complicate this path. Not recommended as a long-term solution.
Bottom Line
The compounded GLP-1 landscape has shifted substantially in 2025-2026. Patients who built their weight-loss approach around $300/month compounded subscriptions face real changes. The good news is that multiple legitimate paths still exist: insurance-covered Wegovy, manufacturer savings programs, compliant patient-specific compounding, and alternative medications. The bad news is that the dramatic price advantage of the 2022-2024 era is largely gone for most patients without underlying clinical justification for compounding. Working with your physician to navigate insurance coverage is the highest-value next step.
Sources
- FDA. "Drug Shortages: Semaglutide Determination." February 2025. (Official shortage list removal)
- FDA. "Section 503A of the FD&C Act - Compounding Guidelines." 2024. (Regulatory framework)
- FDA. "Letter to Compounders Re: Salt Forms of Semaglutide." October 2023. (Salt form clarification)
- Novo Nordisk. "Wegovy Patient Assistance Programs." 2026. (Manufacturer support resources)